Loading…
Lobbying Income
$40K
Filings
9
Unique Clients
3
Active Period
2026
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Newborn Screening Saves Lives Reauthorization Act of 2025
2026 · third_quarter · Client: BEREN THERAPEUTICS
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Client expense: — · Firm income: —
Matched citations: H.R. 4709
Genomic Answers for Children’s Health Act of 2026
2026 · third_quarter · Client: BEREN THERAPEUTICS
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Client expense: — · Firm income: —
Matched citations: H.R. 7118
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · third_quarter · Client: BEAM THERAPEUTICS
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Most Favored Patient Act of 2026
2026 · third_quarter · Client: BEAM THERAPEUTICS
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7837
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7871
Protect Patients from Costly Care Act
2026 · third_quarter · Client: AGIOS PHARMACEUTICALS
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5094
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · third_quarter · Client: AGIOS PHARMACEUTICALS
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Newborn Screening Saves Lives Reauthorization Act of 2025
2026 · second_quarter · Client: BEREN THERAPEUTICS
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Client expense: — · Firm income: —
Matched citations: H.R. 4709
Genomic Answers for Children’s Health Act of 2026
2026 · second_quarter · Client: BEREN THERAPEUTICS
Issues related to patient access to innovative therapies,H.R. 4709 - Newborn Screening Saves Lives Reauthorization, H.R. 7118 - Genomic Answers for Children's Health
Client expense: — · Firm income: —
Matched citations: H.R. 7118
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · second_quarter · Client: BEAM THERAPEUTICS
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Most Favored Patient Act of 2026
2026 · second_quarter · Client: BEAM THERAPEUTICS
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7837
Issues related to patient access to innovative therapies, H.R. 7871 - MVP Act, H.R. 5187 - Sickle Cell Disease, H.R. 7837 - Most Favored Nation Drug Pricing
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7871
Protect Patients from Costly Care Act
2026 · second_quarter · Client: AGIOS PHARMACEUTICALS
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5094
To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity.
2026 · second_quarter · Client: AGIOS PHARMACEUTICALS
Issues related to patient access to innovative therapies, H.R. 5187 - Sickle Cell Disease H.R. 5094 - Orphan Drugs
Client expense: — · Firm income: $10,000
Matched citations: H.R. 5187
Source: Senate LDA